期刊
ATHEROSCLEROSIS
卷 195, 期 1, 页码 7-16出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2006.10.001
关键词
HMG-CoA reductase inhibitors; statins; myopathy; side effects; adverse effects; cancer; neuropathy; renal effects
Randomized controlled trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have consistently demonstrated significant reductions in cardiovascular morbidity and mortality. Statins are currently the most widely used drugs in many countries. The most important adverse effects are associated with muscle and liver toxicity. However, with increased use and dose of statins and their over-the-counter availability in some countries more cases of other rare side effects may be seen in clinical practice. In the present article we review the literature concerning the statin-related adverse effects other than muscle and liver injury and we provide insight into their clinical revelance and possible underlying mechanisms. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据